We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+12.38%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$4.12B
AUM Growth
+$545M
Cap. Flow
+$53M
Cap. Flow %
1.29%
Top 10 Hldgs %
48.24%
Holding
158
New
26
Increased
23
Reduced
71
Closed
24

Top Buys

Rank Stock Value
1
KLRS
Kalaris Therapeutics
KLRS
+$69M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$68.4M
3
BEKE icon
KE Holdings
BEKE
+$43.5M
4
IGMS
IGM Biosciences
IGMS
+$40.8M
5
ITOS
iTeos Therapeutics
ITOS
+$29.4M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$42.9M
2
PYPL icon
PayPal
PYPL
+$34.8M
3
AVTR icon
Avantor
AVTR
+$34M
4
ARGX icon
argenx
ARGX
+$30.2M
5
Z icon
Zillow
Z
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 57.99%
2 Miscellaneous 26.49%
3 Consumer Discretionary 10.25%
4 Technology 2.5%
5 Real Estate 1.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$477B
$572M 13.88%
+2,058,000
New +$558M
WW
2
DELISTED
WW International
WW
$280M 6.79%
14,818,300
– –
ONC
3
BeOne Medicines Ltd
ONC
$39.2B
$258M 6.26%
900,000
+50,000
+6% +$11.8M
GS icon
4
CALL
Goldman Sachs
GS
$288B
$176M 4.27%
875,000
+675,000
+338% +$137M
XLRN
5
DELISTED
Acceleron Pharma
XLRN
$158M 3.82%
1,400,000
– –
BABA icon
6
Alibaba
BABA
$272B
$125M 3.03%
425,000
+52,500
+14% +$13.8M
BNTX icon
7
BioNTech
BNTX
$24.3B
$120M 2.91%
1,731,214
-268,786
-13% -$19.3M
ALNY icon
8
Alnylam Pharmaceuticals
ALNY
$33.3B
$116M 2.83%
800,000
-100,000
-11% -$14.2M
JPM icon
9
CALL
JPMorgan Chase
JPM
$931B
$96.3M 2.34%
1,000,000
-2,000,000
-67% -$196M
GBIO
10
DELISTED
Generation Bio
GBIO
$87M 2.11%
281,419
– –
LXRX icon
11
Lexicon Pharmaceuticals
LXRX
$890M
$86.7M 2.11%
60,240,864
– –
ARGX icon
12
argenx
ARGX
$61.6B
$85.1M 2.07%
324,200
-125,800
-28% -$30.2M
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$83M 2.02%
+500,000
New +$68.4M
GDS icon
14
GDS Holdings
GDS
$6.18B
$81.8M 1.99%
1,000,000
-100,000
-9% -$8.01M
KLRS
15
Kalaris Therapeutics
KLRS
$80.5M
$63.9M 1.55%
+101,016
New +$69M
FATE icon
16
Fate Therapeutics
FATE
$277M
$60M 1.46%
1,500,000
-300,000
-17% -$10.5M
BEKE icon
17
KE Holdings
BEKE
$18.4B
$53.3M 1.29%
+870,000
New +$43.5M
IGMS
18
DELISTED
IGM Biosciences
IGMS
$50.8M 1.23%
+688,910
New +$40.8M
BAC icon
19
CALL
Bank of America
BAC
$416B
$48.2M 1.17%
2,000,000
+1,000,000
+100% +$24.9M
BDTX icon
20
Black Diamond Therapeutics
BDTX
$114M
$46M 1.12%
1,521,517
-25,000
-2% -$761K
MORF
21
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$45.2M 1.1%
1,651,686
-17,500
-1% -$459K
SRRK icon
22
Scholar Rock
SRRK
$6.75B
$44.1M 1.07%
2,495,140
-28,900
-1% -$430K
ABBV icon
23
CALL
AbbVie
ABBV
$454B
$43.8M 1.06%
500,000
+250,000
+100% +$23.5M
SDGR icon
24
Schrodinger
SDGR
$1.42B
$42.6M 1.04%
897,445
– –
FOLD
25
DELISTED
Amicus Therapeutics
FOLD
$42.4M 1.03%
3,000,000
-500,000
-14% -$7.29M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2020 Portfolio in Review

As of Q3 2020, Artal Group held 158 positions worth $4.12B, up 15% from $3.57B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group's Q3 2020 filing shows 26 new, 23 increased, 71 reduced and 24 closed positions. Its largest new stake was Kalaris Therapeutics: 101,016 shares worth $63.9M. The largest sale was Blueprint Medicines, an estimated $42.9M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 62% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

  • Artal Group's largest Q3 2020 buy was Kalaris Therapeutics: 101,016 shares worth $63.9M.
  • Artal Group added most to Agenus in Q3 2020, an estimated $16.1M increase.
  • Artal Group's biggest Q3 2020 reduction was argenx, cutting an estimated $30.2M.
  • Artal Group fully exited Blueprint Medicines in Q3 2020, selling an estimated $42.9M.
  • Artal Group's ten largest holdings make up 48% of its $4.12B portfolio in Q3 2020.
  • Artal Group opened 26 new positions and closed 24 in Q3 2020.
  • Artal Group's portfolio value rose 15% quarter-over-quarter to $4.12B.

Based on Artal Group's 13F filing for Q3 2020, filed 13 Nov 2020.